RecruitingNCT04761393

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Characterizing Mmp12 In Sputum And Its Relationship To Emphysema And Inflammatory Endotypes


Sponsor

McMaster University

Enrollment

45 participants

Start Date

Nov 29, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.


Eligibility

Min Age: 40 YearsMax Age: 85 Years

Inclusion Criteria7

  • ≥40 years of age
  • Current or ex-smokers with a >10 pack year smoking history
  • Have a post-bronchodilator forced expired volume in 1 second (FEV1)/forced expired vital capacity (FVC) ratio of <70% and a post-bronchodilator FEV1 value from ≥30% predicted (GOLD 1, 2 and 3), (Global Initiative for Obstructive Lung disease)
  • Have a radiologist confirmed pulmonary emphysema diagnosis based on CT
  • No clinically significant medical condition or a history of asthma, COPD, cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
  • No current or past smoking history
  • Have a post-bronchodilator FEV1/FVC ratio of >70%

Exclusion Criteria17

  • Any potential subject who meets any of the following criteria will be excluded from participating in the study:
  • Patients with other non-COPD airway diseases
  • Patients with very severe COPD (FEV1<30% predicted)
  • Patients with an intercurrent exacerbation
  • Patients with life expectancy less than 3 months
  • Pregnant or breastfeeding
  • Undergoing immunomodulatory or biologic treatment
  • Use of systemic steroids in the last month
  • Hospitalization in the last 12 months due to exacerbation
  • Known cardiovascular comorbidity under treatment or with hospitalizations of this cause in the last year
  • That they cannot perform spirometry
  • Active malignancy
  • Realization of lung surgery during the study period
  • History of alcohol and drug abuse that prevents compliance with follow-up
  • History of bronchial thermoplasty
  • Participating in another study concomitantly
  • MRI Related: patients who have implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, artificial limb, metallic fragments of foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHyperpolarized 129Xe (Xenon) diffusion-weighted MRI

Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds


Locations(1)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare

Hamilton, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04761393


Related Trials